LifeMD, Inc. $LFMD Shares Sold by UBS Group AG

UBS Group AG decreased its holdings in LifeMD, Inc. (NASDAQ:LFMD) by 21.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 674,008 shares of the company’s stock after selling 189,014 shares during the quarter. UBS Group AG’s holdings in LifeMD were worth $2,298,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its position in LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after buying an additional 2,452 shares during the last quarter. Quarry LP purchased a new position in LifeMD during the 3rd quarter worth approximately $52,000. State of Alaska Department of Revenue grew its position in LifeMD by 694.2% during the 4th quarter. State of Alaska Department of Revenue now owns 20,022 shares of the company’s stock worth $67,000 after purchasing an additional 17,501 shares in the last quarter. SG Americas Securities LLC grew its position in LifeMD by 13.8% during the 4th quarter. SG Americas Securities LLC now owns 25,298 shares of the company’s stock worth $86,000 after purchasing an additional 3,061 shares in the last quarter. Finally, Magnus Financial Group LLC purchased a new position in LifeMD during the 4th quarter worth approximately $41,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Stock Up 7.8%

LifeMD stock opened at $4.57 on Thursday. The company’s fifty day simple moving average is $4.16 and its 200-day simple moving average is $3.78. LifeMD, Inc. has a 12 month low of $2.56 and a 12 month high of $15.84. The stock has a market cap of $221.01 million, a P/E ratio of 91.42 and a beta of 2.03.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.06). LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. The company had revenue of $50.16 million for the quarter, compared to analysts’ expectations of $48.84 million. On average, equities research analysts expect that LifeMD, Inc. will post 0.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LFMD. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research report on Tuesday. Mizuho upgraded shares of LifeMD from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $6.00 to $8.00 in a research report on Monday, March 16th. Weiss Ratings upgraded shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. Loop Capital set a $10.00 price objective on shares of LifeMD in a research report on Thursday, March 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of LifeMD in a research report on Tuesday, March 10th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.14.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.